InMed Pharmaceuticals Inc. (INM) News
Track canonical SquawkNews coverage tagged to INM, InMed Pharmaceuticals Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
InMed had a Pre-IND meeting with FDA on INM-901
InMed said it held a Pre-IND meeting with the FDA for its INM-901 program. The company also said it is integrating FDA feedback into its development planning.
MACRO | Sep 09, 2026, 10:02 PM UTC
L
InMed Pharmaceuticals FY Loss Cont Ops $2.84/Shr
InMed Pharmaceuticals FY Loss Cont Ops $2.84/Shr
EQUITY | Sep 09, 2026, 10:00 PM UTC
L
InMed Pharmaceuticals FY Loss/Shr $3.12
InMed Pharmaceuticals FY Loss/Shr $3.12
EQUITY | Sep 09, 2026, 09:59 PM UTC
L
InMed Pharmaceuticals reports fiscal 2026 revenue of $3.18M and EPS loss of $3.12
The company reported fiscal 2026 revenue of $3.18 million, largely from discontinued BayMedica commercial operations. Net loss attributable to common shareholders was $13 million, and diluted loss per share was ($3.12).
EARNINGS | Sep 09, 2026, 08:48 PM UTC
L
INM reports FY 2026 net loss of $12.6M after revenue operations ceased
INM reported a $12.6 million net loss for FY 2026 and said its cash reserves are expected to fund operations into Q3 2026. The company wound down its only revenue-generating segment and said its future depends on a pendi
EARNINGS | Sep 09, 2026, 08:35 PM UTC
L
InMed reports full-year fiscal 2026 financial results and corporate update
EQUITY | Sep 09, 2026, 08:31 PM UTC
H
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
() -- InMed Pharmaceuticals (INM) entered into an amendment to its definitive merger agreement for an all-stock transaction with Mentari Therapeutics and its subsidiaries that clarifies details of the deal, the company s
MNA | Jul 07, 2026, 07:40 AM UTC
H
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
InMed Pharmaceuticals announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company
MNA | Jul 06, 2026, 11:01 PM UTC